产品说明书
MJN110
 |
同义名 : | 2,5-Dioxopyrrolidin-1-yl 4-[bis(4-chlorophenyl)methyl]piperazine-1-carboxylate |
| CAS号 : | 1438416-21-7 | |
| 货号 : | A1193393 | |
| 分子式 : | C22H21Cl2N3O4 | |
| 纯度 : | 98% | |
| 分子量 : | 462.326 | |
| MDL号 : | MFCD26960823 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 250 mg/mL(540.74 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | The monoacylglycerol lipase (MAGL) is a serine hydrolase responsible for the degradation of 2-arachidonoyl glycerol (2-AG). MJN110 is a potent and selective MAGL inhibitor with an IC50 value of 9.1nM. In human prostate cancer PC3 cells, treatment with MJN110 for 4 hours inhibited MAGL with an IC50 value of ~1nM. MJN110 also potently inhibited the 2-AG hydrolysis of in mouse brain homogenates with an IC50 value of 2.1nM without affecting the hydrolysis of N-arachidonoyl ethanolamine up to 50μM. The oral treatment of MJN110 (0.5–5.0mg/kg) in mice dose-dependently inhibited MAGL expression in the brain and liver. It also inhibited MAGL in vivo when administered intraperitoneally with the maximal inhibition observed at 0.25mg/kg in the live and 1.0mg/kg in the brain. The oral administration of MJN110 led to a 2-fold increase in 2-AG at the dose of 0.5mg/kg and a 10-fold increase at 5.0mg/kg. MJN110-treated mice also showed dose-dependent reduction of arachidonic acid in the brain[1]. | ||
| 作用机制 | MJN110 inhibits MAGL via the carbamylation of MAGL’s active-site serine nucleophile[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.16mL 0.43mL 0.22mL |
10.81mL 2.16mL 1.08mL |
21.63mL 4.33mL 2.16mL |
| 参考文献 |
|---|